Polygiene Group AB (POLYG) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the presentation of the third quarter Apollogene Group. I am Erika Bjork and I'm the CEO of the company. And I'm Niklas Blomstedt and I am the CFO. I'm going to start to show you some highlights of the quarter. It's been an interesting journey the last six months. I'm going to show you here some of the The headlines. So what we could see coming out of a quite poor Q2, we have seen improved performance and especially driven by a faster recovery in PolyGene. Admasters still have a little bit more time to come back after the drop in Q2. But we can see the businesses overall returning slowly. And Admasters have received some quite significant big orders in the beginning of October here. So we believe that the end, the year end will be very, very strong for us. We also held our first global agent and distributor conference in September. We had one in Malmo and one in Manchester, and that is to strengthen the external sales force we have. And then very, very interesting is that we've seen the first commercial orders for Stay Cool. And I will come back to that a little bit later when I go more in depth. And then tomorrow's news about the patent we filed for a new groundbreaking technology within mosquito applications. But first, we're going to have a summary of the financial updates. Yes, if we start with a short summary, we can see that sales was 36.4% versus 40.8%. It's down with 10.8%. But the FX effect is 7%, so it's around 4 or 5% that's the volume driven, the rest is FX. We see a gross margin of 71.1 versus 71.6. But if you compare quarter to quarter, we can see that there is a negative FX impact of 2% versus last year. So without FX, the margin would actually be stronger this year versus last year. And that's mainly driven by the mix we ha...